Nls pharmaceutics presents latest clinical and preclinical data at sleep 2023

Oral presentation sharing significant phase 2 results of mazindol er in adults with narcolepsy type 1 and type 2 five abstracts demonstrating nls focus on and investment in hypersomnia disorders and rare and complex neurologic diseases zurich, switzerland / accesswire / may 4, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will present clinical data for the lead compound, mazindol er, as well as preclinical data on its pipeline compound, nls-4, at sleep 2023, the annual meeting of the american academy of sleep medicine (aasm) and the sleep research society (srs), which is being held from june 3 - 7, 2023, in indianapolis.
NLSP Ratings Summary
NLSP Quant Ranking